自体骨髓间充质干细胞联合自体外周血造血干细胞移植治疗恶性血液病

目的:观察自体骨髓间充质干细胞(mesenchymal stem cells,MSCs)联合自体外周血造血干细胞(autologous peripheral blood stem cells,APBSCs)移植治疗恶性血液病的可行性、有效性和相关并发症发生情况。方法:采用无血清培养体系体外培养MSCs,将自体骨髓MSCs与APBSCs共移植治疗12例恶性血液病患者,并与同期进行的12例未联合MSCs的自体外周血造血干细胞移植(peripheral blood stem cells transplantation,APBSCT)的恶性血液病患者进行造血恢复及并发症比较。结果:MSCs输注无明显不良反应;联合移植的患者,造血恢复中性粒细胞(ANC)≥0.5×109/L平均9.52 d,血小板(PBC)≥20×109/L平均9.05 d,较对照组恢复快(P<0.05);血清丙氨酸氨基转移酶(ALT)和血清天门冬氨酸氨基转移酶(AST)较对照组低(P<0.05);口腔溃疡和感染发生率与对照组比较差异无统计学意义(P>0.05)。结论:MSCs与APBSCs联合移植治疗恶性血液病安全可行,移植后造血重建快,并发症少。

Co-transplantation of autologous marrow mesenchymal stem cells and autologous peripheral blood stem cells for patients with hematologic malignancies

Objective:To observe the feasibility,efficacy and related complications of co-transplantation of autologous marrow mesenchymal stem cells(MSCs) and autologous peripheral blood stem cells(APBSCs) for patients with hematologic malignancies.Methods: MSCs were expanded in vitro in mesencult serum-free media.Hematopoietic recovery and related complications of twelve patients receiving co-transplantation of APBSCs and MSCs were compared with that of twelve patients only receiving transplantation of peripheral blood stem cells.Results:There was no obvious toxicity related to the infusion of MSCs.In co-transplantation group,the times for hematopoietic recovery of ANC≥0.5×109 /L and PBC≥20×109 /L were 9.52 days and 9.05 days,respectively,shorter than that in control groups(P<0.05),the activity of serum alanine aminotransferase(ALT) and serum aminotransferase(AST) was lower(P<0.05) than that in control group,and the incidences of oral ulcers and infection were not significantly different with that in control group(P>0.05).Conclusion:The co-transplantation of MSCs and APBSCs is feasible and safe for patients with hematologic malignancies,and the hematopoietic recovery is rapid while the related complication is less.